Acute Repetitive Seizures Market Size & Share 2024 – 2032

Acute Repetitive Seizures Market Size

The global acute repetitive seizures (ARS) market in 2023 was valued at USD 2.7 billion and is poised to grow at 12.4% CAGR from 2024 to 2032. The market is growing significantly due to the increasing prevalence of epilepsy and advancements in rescue therapies.

Epilepsy is one of the most common neurological conditions across the globe, with there being 50 million cases globally according to WHO. Correspondingly, the Centers for Disease Control and Prevention (CDC) has stated that there are roughly 3.4 million active epilepsy patients across the U.S., which includes 470,000 children. This simply indicates the significant opportunity for treatments within the targeted region.
 

Additionally, the USL-261 (intranasal midazolam) and NRL-1 (intranasal diazepam) formulations have been proven to be significant for the market of acute repetitive seizures. Non-invasive fast-acting treatment is easier for a wide range of people including patients, caregivers, children and elderly, boosting its demand and increasing its market growth. It allows easy access to treatments which will eliminate the need for medical supervision, thereby contributing to market growth.
 

Acute repetitive seizures (ARS), also termed flurries and seizure clusters, refer to a sequence of seizures that occur close together within a 24 to 48-hour timeframe. If not dealt with quickly, it could escalate to status epilepticus, which can be life-threatening. ARS occurs frequently in epilepsy patients who face difficulty in controlling their seizures, making it a critical focus for treatment solutions. Management of ARS typically involves rescue drugs such as medications which are useful in stopping seizure activity from worsening, especially benzodiazepine drugs like diazepam midazolam. The aim of treatment is to decrease the number of times seizures occur, avert additional clusters, and guard against complications.
 

Acute Repetitive Seizures Market Trends

• The increasing rate of people suffering from epilepsy and seizure disorders fuels the growth of ARS market.
   
• The National Institute of Neurological Disorders and Stroke (NINDS) states epilepsy affects people of all ages, with onset most common in children and older adults. It is estimated that around 1 in 26 people will be diagnosed with epilepsy. Further, Epilepsy Foundation reports that out of all the people suffering from epilepsy 30-40% still have active seizures despite treatment. Among these, many experience seizure clusters or acute repetitive seizures.
   
• With the increase in numbers of patients in need of epilepsy care, there arises the need for treatment of other associated complications including seizure clusters (SC) or acute repetitive seizures (ARS), that exist among people with epilepsy PWE.
   
• As the community of patients diagnosed with epilepsy report having seizure clusters, the need for effective ARS treatments is rising, contributing to market growth.
   
• In addition, the need for non-invasive, rapid treatment has gained the attention of pharmaceutical companies. As a result, companies have invested in developing fast-acting treatments like intranasal rescue medications, driving market expansion.
   

Acute Repetitive Seizures Market Analysis

Based on product, the market is classified into USL-261, diastat rectal gel (DRG), NRL-1, and other products. The USL-261 segment held market share of 35.2% in 2023.
 

• The convenience and the non-invasive nature of the USL-261 solution has significantly driven the growth of this segment. Furthermore, seizure management. Additionally, owing to the advantages including rapid absorption and swift seizure control provided by intranasal delivery systems in emergency situations further propels the market growth.
   
• Another factor leading to the significant market share of this segment is that it has FDA approval to treat seizure clusters in patients suffering from epilepsy, which increases its market credibility and makes it widely accepted.
   
• In addition, USL-261’s adoption has been further propelled by the increasing preference for homebased seizure control that requires easy to use rescue therapies.
   

Based on route of administration, the acute repetitive seizures market is segmented into intranasal, rectal, oral, and other routes of administration. The intranasal segment was valued at USD 1.2 billion in 2023.
 

• Growth of intranasal drug delivery systems is fostered by its non-invasive nature, convenience and quick drug delivery which is crucial in treating seizure attacks.
   
• Nasal mucosa facilitates drug absorption which ensures rapid action, thereby averting the severe conditions that could accompany uncontrolled seizures such as status epilepticus.
   
• In addition, the growing tendency towards homecare has fostered rapid adoption of these therapies such as USL-261 and NRL-1 that do not need clinical supervision.

Learn more about the key segments shaping this market

Download Free PDF

Based on distribution channel, the acute repetitive seizures market is bifurcated into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is expected to grow at a CAGR of 12.2% during the analysis timeframe.
 

• The rise in the occurrence of acute repetitive seizures makes hospitalization inevitable, thereby intensifying the need for effective seizure medications in hospital pharmacies.
   
• Moreover, these pharmacies often work in collaboration with the neurologists and the emergency care professionals to develop protocols aimed at improving the outcomes and accessibility of treatment for these patients.
   
• Qwing of these factors, the hospital pharmacies segment is expected to experience steady growth in the subsequent years.

North America acute repetitive seizures market was valued at USD 1.1 billion in 2023 and is expected to grow lucratively at 12.3% CAGR.
 

• The increasing prevalence of the disease in the region is driving the demand for developing effective treatments for epilepsy. Additionally, the well-established healthcare system in the country enables accurate diagnosis and management of the condition.
   
• For instance, the National Association of Epilepsy Centers (NAEC) states that over 260 specialised epilepsy centers in the U.S. alone, thus increasing the ability to render healthcare services.
   
• The increased awareness and education about the condition further contributes to the market growth.
   
• Additionally, the improvement in patient care, the faster-acting and non-invasive medications, and the greater level of approval for the new therapies creates more available options within the market.
   
• These factors collectively contribute to the market's substantial growth potential.
   

In 2023, the U.S. acute repetitive seizures market was valued at USD 1 billion and is projected to reach USD 2.8 billion by 2032.
 

• According to the statistics shared by the Centers for Disease Control and Prevention (CDC), in the U.S., approximately 2.9 million people aged 18 and older are active epilepsy patients, which takes up nearly 1% of the population.
   
• This statistic indicates that a huge section of the population is susceptible to ARS which amplifies the market demand for these ARS treatment options thereby contributing to the market's growth potential.
   

China acute repetitive seizures market is predicted to showcase remarkable growth over the forecast period.
 

• The funding had indeed increased, coupled with the growing number of people afflicted with epilepsy has driven the government to allocate more resources into the healthcare sector, which improves the diagnosis treatment for seizure disorders. According to the World Health Organization, the prevalence of epilepsy in China is estimated to be 7 per 1,000 population, affecting approximately 9 million people.
   
• Moreover, the treatment of ARS is being made accessible through an increase in specialized neurological clinics and hospitals. These factors mentioned above are likely to foster or support growth in the country’s market.
   

India is expected to witness significant growth in Asia Pacific acute repetitive seizures market.
 

• With an estimated prevalence of around 1 to 2 % of the population affected by epilepsy, an increase in the prevalence of these neurological conditions is likely to lead to a higher demand for efficient ARS therapies.
   
• In India, government initiatives, such as Ayushman Bharat enable more people to be able to undergo the necessary treatments. Furthermore, there is also growing spending on research and development in the pharmaceutical industry for innovative therapies focused on ARS.
   
• These aforementioned factors are expected to support market growth in the country.
   

Acute Repetitive Seizures Market Share

The market is very competitive due to established pharmaceutical companies as well as newer biotech companies. This competitive advantage is also complemented by efforts in research and development focused on the introduction of new novel therapies. The market is witnessing various companies collaborating with healthcare providers to enhance the efficacy of seizure management solutions.
 

Acute Repetitive Seizures Market Companies

Prominent players operating in the acute repetitive seizures industry include:

• AdvaCare Pharma Limited
• Aquestive Therapeutics
• Bausch Health Companies
• Lupin Limited
• Neuracle Lifesciences
• Neurelis
• Pfizer
• Sanofi
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries
• UCB S.A.
• Veriton Pharma
   

USPs of top players:

• Investment in research and development for novel drug delivery systems.
   
• Establishment of specialized distribution networks for emergency medications.
   
• Strategic partnerships with healthcare providers and research institutions.
   

Acute Repetitive Seizure Industry News:

• In April 2024, the FDA approved Libervant buccal film by Aquestive Therapeutics for treating intermittent, stereotypic episodes of frequent seizure activity, including seizure clusters and acute repetitive seizures, in patients aged 2 to 5 years. This approval helped the company to expand its product offerings in the paediatric market, potentially increasing revenue and enhancing its reputation in innovative seizure management therapies.
   

The acute repetitive seizures market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• USL-261
• Diastat rectal gel (DRG)
• NRL-1
• Other products

Market, By Route of Administration

• Intranasal
• Rectal
• Oral
• Other routes of administration

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
• U.S.
• Canada

• Europe
• Germany
• UK
• France
• Spain
• Italy
• Netherlands
• Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Latin America
• Brazil
• Mexico
• Argentina
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE